Release Date |
|
| Feb 9, 2012 |
Advaxis to Present at the 14th Annual BIO CEO & Investor Conference |
| Jan 26, 2012 |
REPEAT/Advaxis Reports Preliminary Safety and Survival Data from a Phase 2 Trial in Recurrent/Refractory Cervical Cancer |
| Jan 26, 2012 |
Advaxis CEO Tom Moore Interviewed by OneMedPlace Regarding Preliminary Data |
| Jan 25, 2012 |
Advaxis Reports Preliminary Safety and Survival Data from a Phase 2 Trial in Recurrent/Refractory Cervical Cancer |
| Jan 11, 2012 |
Dosing Begins for GOG US Cervical Cancer Study Evaluating ADXS-HPV |
| Jan 6, 2012 |
Advaxis to Present at 5th Annual OneMedForum San Francisco 2012 |
| Dec 30, 2011 |
Advaxis Receives Additional Financing |
| Dec 16, 2011 |
Advaxis Reports Preliminary Data from ADXS-HPV Phase 2 Trial in Patients with Recurrent/Refractory Cervical Cancer at AACR India |
| Nov 23, 2011 |
Advaxis Completes Pre-IND Meeting for ADXS-HER2 |
| Nov 15, 2011 |
Advaxis Licenses Novel Antigen for Severe Breast Cancer and Other Tumor Types |
| Oct 28, 2011 |
Advaxis Receives Additional Financing |
| Oct 18, 2011 |
Advaxis Announces Notice of Allowance of US Patent for ADXS-HPV Immunotherapy |
| Oct 17, 2011 |
Advaxis to Present at the 2011 10th Annual BIO Investor Forum on October 25th |
| Oct 13, 2011 |
Advaxis ADXS-HPV Project Selected as One of the Windhover and Campbell Alliance 2011 Top 10 Most Interesting Oncology Projects to Watch |
| Oct 11, 2011 |
Advaxis Granted Pre-IND Meeting with FDA for ADXS-HER2, an Immunotherapy for HER2 Expressing Cancers |
| Sep 6, 2011 |
Advaxis Will Present at the Rodman & Renshaw 13th Annual Healthcare Conference on September 13th, 2011 |
| Aug 30, 2011 |
Advaxis Announces 2011 Annual Meeting of Stockholders |
| Aug 25, 2011 |
Diana Moore Appointed as Director, Investor Relations & Business Development at Advaxis, Conrad Mir Departs |
| Jul 20, 2011 |
Dr. Ashok Amin Joins Advaxis as Vice President of Research and Development |
| Jul 11, 2011 |
Advaxis Completes Enrollment of Low Dose Cohort in CIN Study |
